ClinicalTrials.gov
ClinicalTrials.gov Menu

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02808403
Recruitment Status : Recruiting
First Posted : June 21, 2016
Last Update Posted : November 27, 2017
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
The purpose of this post-marketing survey is to obtain real-world information on the safety and effectiveness of evolocumab in Japan.

Condition or disease Intervention/treatment
Hypercholesterolemia Familial Hypercholesterolemia Other: No intervention

Detailed Description:
The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history) associated with the safety and effectiveness of evolocumab therapy for the patients with Familial Hypercholesterolemia (Heterozygous or Homozygous) and Hypercholesterolemia in Japan

Study Type : Observational
Estimated Enrollment : 6000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab (AMG 145) in Japan
Actual Study Start Date : June 24, 2016
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Evolocumab

Group/Cohort Intervention/treatment
Evolocumab exposed
Patients for whom evolocumab is prescribed. Dosage, period (start/end date), frequency of injection (Every 2 weeks (Q2W), Every 4 weeks (Q4W)), drug withdrawal (Yes or No, date, reason) and injection site (upper arm, abdomen, thigh) of evolocumab will be collected.
Other: No intervention
No intervention; observation of routine medical care




Primary Outcome Measures :
  1. Incidence of adverse events and adverse drug reactions [ Time Frame: 2 years ]
    The incidence of adverse events and drug reactions will be described using the same units (events per 1000 person-years). Adverse events (including seriousness and causal relations to drug or device), inclusive of reaction at local injection sites, and other safety information (e.g. overdose, lack of effectiveness, pregnancy and lactation with or without adverse event) will be described.

  2. Laboratory values for LDL-C [ Time Frame: 2 years ]
  3. Laboratory values for HDL-C [ Time Frame: 2 years ]
  4. Laboratory values for total cholesterol [ Time Frame: 2 years ]
  5. Laboratory values for triglycerides [ Time Frame: 2 years ]
  6. Laboratory values for Apolipoprotein (Apo) A1 [ Time Frame: 2 years ]
    This will be measured if feasible.

  7. Laboratory values for Apolipoprotein (Apo) Apo B [ Time Frame: 2 years ]
    This will be measured if feasible.

  8. Laboratory values for Apolipoprotein (Apo) Apo E [ Time Frame: 2 years ]
    This will be measured if feasible.

  9. Laboratory values for lipoprotein(a) [ Time Frame: 2 years ]
    This will be measured if feasible.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients for whom evolocumab is prescribed at participating medical institutions in accordance with the approved Japan prescribing information (i.e., those with Familial Hypercholesterolemia and Hypercholesterolemia who have high risk factors for cardiovascular event and do not respond sufficiently to Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) for hypercholesterolemia.)
Criteria

Inclusion Criteria:

  • Patients for whom evolocumab is prescribed at participating medical institutions in accordance with the approved Japan prescribing information (i.e., those with Familial Hypercholesterolemia (Heterozygous or Homozygous and Hypercholesterolemia who have high risk factors for cardiovascular event and do not respond sufficiently to HMGCoA reductase inhibitor (statin) for hypercholesterolemia).

Exclusion Criteria:

  • No exclusion criteria are applied.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02808403


Contacts
Contact: Amgen Call Center 866-572-6436

  Show 139 Study Locations
Sponsors and Collaborators
Amgen
Investigators
Study Director: MD Amgen

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02808403     History of Changes
Other Study ID Numbers: 20140409
First Posted: June 21, 2016    Key Record Dates
Last Update Posted: November 27, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipoproteinemia Type II
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs